These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 26857837)

  • 1. Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice.
    Hu J; Che L; Li L; Pilo MG; Cigliano A; Ribback S; Li X; Latte G; Mela M; Evert M; Dombrowski F; Zheng G; Chen X; Calvisi DF
    Sci Rep; 2016 Feb; 6():20484. PubMed ID: 26857837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans.
    Che L; Chi W; Qiao Y; Zhang J; Song X; Liu Y; Li L; Jia J; Pilo MG; Wang J; Cigliano A; Ma Z; Kuang W; Tang Z; Zhang Z; Shui G; Ribback S; Dombrowski F; Evert M; Pascale RM; Cossu C; Pes GM; Osborne TF; Calvisi DF; Chen X; Chen L
    Gut; 2020 Jan; 69(1):177-186. PubMed ID: 30954949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.
    Li L; Pilo GM; Li X; Cigliano A; Latte G; Che L; Joseph C; Mela M; Wang C; Jiang L; Ribback S; Simile MM; Pascale RM; Dombrowski F; Evert M; Semenkovich CF; Chen X; Calvisi DF
    J Hepatol; 2016 Feb; 64(2):333-341. PubMed ID: 26476289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin delays AKT/c-Met-driven hepatocarcinogenesis by regulating signaling pathways for de novo lipogenesis and ATP generation.
    Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Zheng G; Qiu Z
    Toxicol Appl Pharmacol; 2019 Feb; 365():51-60. PubMed ID: 30625338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.
    Wang C; Cigliano A; Delogu S; Armbruster J; Dombrowski F; Evert M; Chen X; Calvisi DF
    Cell Cycle; 2013 Jul; 12(13):1999-2010. PubMed ID: 23759595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Celecoxib alleviates AKT/c-Met-triggered rapid hepatocarcinogenesis by suppressing a novel COX-2/AKT/FASN cascade.
    Qiu Z; Zhang C; Zhou J; Hu J; Sheng L; Li X; Chen L; Li X; Deng X; Zheng G
    Mol Carcinog; 2019 Jan; 58(1):31-41. PubMed ID: 30182439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.
    Wang C; Che L; Hu J; Zhang S; Jiang L; Latte G; Demartis MI; Tao J; Gui B; Pilo MG; Ribback S; Dombrowski F; Evert M; Calvisi DF; Chen X
    Liver Int; 2016 Aug; 36(8):1176-86. PubMed ID: 26716908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
    Xu Z; Hu J; Cao H; Pilo MG; Cigliano A; Shao Z; Xu M; Ribback S; Dombrowski F; Calvisi DF; Chen X
    Exp Mol Med; 2018 Jan; 50(1):e417. PubMed ID: 29303510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
    Evert M; Calvisi DF; Evert K; De Murtas V; Gasparetti G; Mattu S; Destefanis G; Ladu S; Zimmermann A; Delogu S; Thiel S; Thiele A; Ribback S; Dombrowski F
    Hepatology; 2012 May; 55(5):1473-84. PubMed ID: 22271091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
    Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
    Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osthole delays hepatocarcinogenesis in mice by suppressing AKT/FASN axis and ERK phosphorylation.
    Mo Y; Wu Y; Li X; Rao H; Tian X; Wu D; Qiu Z; Zheng G; Hu J
    Eur J Pharmacol; 2020 Jan; 867():172788. PubMed ID: 31712058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis.
    Jia J; Che L; Cigliano A; Wang X; Peitta G; Tao J; Zhong S; Ribback S; Evert M; Chen X; Calvisi DF
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33187130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.
    Che L; Pilo MG; Cigliano A; Latte G; Simile MM; Ribback S; Dombrowski F; Evert M; Chen X; Calvisi DF
    Cell Cycle; 2017 Mar; 16(6):499-507. PubMed ID: 28118080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.
    Li L; Che L; Tharp KM; Park HM; Pilo MG; Cao D; Cigliano A; Latte G; Xu Z; Ribback S; Dombrowski F; Evert M; Gores GJ; Stahl A; Calvisi DF; Chen X
    Hepatology; 2016 Jun; 63(6):1900-13. PubMed ID: 26910791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.
    Calvisi DF; Wang C; Ho C; Ladu S; Lee SA; Mattu S; Destefanis G; Delogu S; Zimmermann A; Ericsson J; Brozzetti S; Staniscia T; Chen X; Dombrowski F; Evert M
    Gastroenterology; 2011 Mar; 140(3):1071-83. PubMed ID: 21147110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of mTORC1-driven overproduction of apoB-containing triacylglyceride-rich lipoproteins by short-chain fatty acids, 4-phenylbutyric acid and (R)-α-lipoic acid, in human hepatocellular carcinoma cells.
    Roberts JL; He B; Erickson A; Moreau R
    Biochim Biophys Acta; 2016 Mar; 1861(3):166-76. PubMed ID: 26680362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met.
    Zhang C; Sheng L; Yuan M; Hu J; Meng Y; Wu Y; Chen L; Yu H; Li S; Zheng G; Qiu Z
    Toxicol Appl Pharmacol; 2020 Apr; 392():114918. PubMed ID: 32045588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD147 reprograms fatty acid metabolism in hepatocellular carcinoma cells through Akt/mTOR/SREBP1c and P38/PPARα pathways.
    Li J; Huang Q; Long X; Zhang J; Huang X; Aa J; Yang H; Chen Z; Xing J
    J Hepatol; 2015 Dec; 63(6):1378-89. PubMed ID: 26282231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual regulation of fatty acid synthase (FASN) expression by O-GlcNAc transferase (OGT) and mTOR pathway in proliferating liver cancer cells.
    Raab S; Gadault A; Very N; Decourcelle A; Baldini S; Schulz C; Mortuaire M; Lemaire Q; Hardivillé S; Dehennaut V; El Yazidi-Belkoura I; Vercoutter-Edouart AS; Panasyuk G; Lefebvre T
    Cell Mol Life Sci; 2021 Jul; 78(13):5397-5413. PubMed ID: 34046694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.
    Wang C; Cigliano A; Jiang L; Li X; Fan B; Pilo MG; Liu Y; Gui B; Sini M; Smith JW; Dombrowski F; Calvisi DF; Evert M; Chen X
    Hepatology; 2015 Jan; 61(1):200-13. PubMed ID: 25145583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.